Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00480623 · ClinicalTrials.gov registry record · Phase 1
A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence
A Phase 1 study, sponsored by Agennix.
- Terminated
- Registry status
- Phase 1
- Development phase
NCT00480623: Clinical Trial Phase 1 study, sponsored by Agennix.
NCT00480623 is a Phase 1 study that was terminated before completion, run by Agennix. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00480623, a Phase 1 study, was terminated before completion, sponsored by Agennix.
- TERMINATED
- Registry status
- Phase 1
- Development phase
Study Summary
This study is designed to measure the impact of Satraplatin plus radiation therapy to the bed of the prostate in patients who have developed biochemical failure of their prostate cancer. The main objective of this study is to determine the maximum tolerated dose and dose limiting toxicity for the combination of satraplatin and radiation therapy and to determine the recommended dose for subsequent Phase II trials.
Interventions
- DRUG Satraplatin plus radiation therapy
Trial Details
| Field | Value |
|---|---|
| Start Date | 2007-05 |
| Est. Completion | 2008-04 |
| Phase | Phase 1 |
Why NCT00480623 stopped before completion
NCT00480623 is an interventional study that assigns participants to a tested intervention. An enrollment target was not published in the registry record, which is common for early-stage or observational entries.
The record links to 0 conditions, and to 1 intervention - of which Satraplatin plus radiation therapy is the first listed.
NCT00480623 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00480623 about?
NCT00480623 is a clinical study titled "A Phase I Trial of Satraplatin Plus Radiation Therapy for Prostate Cancer Patients With Biochemical Recurrence". This study is designed to measure the impact of Satraplatin plus radiation therapy to the bed of the prostate in patients who have developed biochemical failure of their prostate cancer. The main objective of this study is to determine the maximum tolerated dose and dose limiting toxicity for the co...
What is the current status of trial NCT00480623?
This trial is currently terminated. It is a Phase 1 study. The study started on 2007-05. Estimated completion is 2008-04.
What interventions are being tested in trial NCT00480623?
The interventions under investigation include: Satraplatin plus radiation therapy (DRUG).
Who is sponsoring clinical trial NCT00480623?
This trial is sponsored by Agennix, which has 13 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia